Analytic Investors’s Regeneron Pharmaceuticals REGN Stock Holding History

Analytic Investors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-29,158	Closed	-$10.2M	–	671
2016 Q2	$10.2M	Buy	+29,158	New	+$11.2M	0.12%	147
2015 Q3	–	Sell	-926	Closed	-$472K	–	621
2015 Q2	$472K	Sell	926 -925	-50%	-$451K	0.01%	463
2015 Q1	$836K	Buy	+1,851	New	+$784K	0.01%	384
2014 Q1	–	Sell	-5,162	Closed	-$1.42M	–	593
2013 Q4	$1.42M	Sell	5,162 -27,280	-84%	-$7.85M	0.02%	283
2013 Q3	$10.2M	Buy	+32,442	New	+$8.53M	0.16%	144

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Analytic Investors's REGN Position: Q3 2016 in Review

Analytic Investors sold out of Regeneron Pharmaceuticals (REGN) in Q3 2016, closing a stake of 29,158 shares — an estimated $10.2M sold.

Analytic Investors first reported a position in REGN in Q3 2013 and held it in 5 quarters. The position peaked at $10.2M in Q2 2016. 553 funds tracked by Wall St. Rank hold REGN as of Q3 2016.

Analytic Investors reported no remaining Regeneron Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Analytic Investors sold 29,158 Regeneron Pharmaceuticals shares in Q3 2016, an estimated $10.2M.
Analytic Investors first reported a position in Regeneron Pharmaceuticals in Q3 2013 and held it in 5 quarters.
Analytic Investors's Regeneron Pharmaceuticals position peaked at $10.2M in Q2 2016.
553 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2016.

Based on Analytic Investors's 13F filing for Q3 2016, filed 14 Nov 2016.